Antihypertensive Management in Post‑Stroke Patients with Persistent Hypertension

Timing of Initiation

Antihypertensive therapy should be restarted or newly initiated after the first 24–72 hours of stabilization following the acute cerebrovascular event to allow safe hemodynamic recovery. 1
In individuals who were already receiving antihypertensive medication before the stroke, treatment should be resumed after the early stabilization period to lower the risk of recurrent stroke. 2
For patients without prior antihypertensive therapy but with a documented office blood pressure ≥140/90 mmHg, medication should be started a few days after the index event. 3

Angiotensin‑converting‑enzyme inhibitors (ACEIs), angiotensin‑receptor blockers (ARBs), calcium‑channel blockers (CCBs), and thiazide‑type diuretics are all classified as first‑line agents for secondary stroke prevention. 4
Use of a thiazide diuretic alone, an ACEI or ARB alone, or the combination of a thiazide diuretic with an ACEI has been shown to reduce the risk of recurrent stroke. 1

The recommended office blood pressure goal for most post‑stroke patients is <130/80 mmHg to minimize the risk of recurrent cerebrovascular and other vascular events. 3
In older adults, a slightly higher target of <140/80 mmHg is acceptable. 4
The target blood pressure should be achieved within 3 months of initiating therapy. 6

Beta‑blockers are not considered first‑line agents for secondary stroke prevention. 5
They are reserved for patients with specific co‑existing conditions, such as coronary artery disease. 3

Although evidence for CCBs in isolated secondary stroke prevention is limited, they are reasonable as add‑on therapy, particularly when additional agents are required. 3
CCBs are especially useful in combination regimens for patients of African descent. 6

In patients with ischemic stroke, lipid‑lowering therapy should aim for an LDL‑C level <70 mg/dL (≈1.8 mmol/L). 4
High‑intensity statin therapy (e.g., atorvastatin 80 mg daily) is indicated to further reduce recurrent stroke risk. 3

Aggressive blood pressure reduction during the first 24–72 hours after stroke is contraindicated unless systolic ≥ 220 mmHg, diastolic ≥ 120 mmHg, or reperfusion therapy mandates tighter control. 1
Monotherapy should be avoided; combination therapy provides superior protection against recurrent events. 6
Abrupt discontinuation of chronic beta‑blocker therapy should be avoided to prevent withdrawal syndrome. 8

Combine agents (e.g., ACEI/ARB + thiazide, or ARB + CCB) rather than using single‑drug regimens for optimal stroke recurrence reduction. 7

Objective adherence assessment methods—such as pharmacy refill records, pill counts, or electronic monitoring devices—should be employed to ensure consistent medication use. 5